Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ICML 2017 | Next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma

Constantine Tam • 14 Jun 2017

ICML 2017

Non-Hodgkin Lymphoma Ibrutinib Venetoclax

Constantine Tam, MBBS, MD, FRACP, FRCPA from the University of Melbourne, Melbourne, Australia discusses the next steps for the use of ibrutinib, venetoclax and other agents for the treatment of lymphoma. Prof. Tam explains that we need to find the best combinations from the drugs that are already known to be active. We also need to learn how to sequence these drugs in order to get the best outcome. Further, we need to learn their weaknesses in order to develop second and third generations drugs that overcome these weaknesses.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.

ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL

Constantine Tam • 11 Dec 2023

The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies

Constantine Tam • 11 Dec 2023

SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL

Constantine Tam • 11 Dec 2023

Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL

Constantine Tam • 11 Dec 2023

Related Videos

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024

Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing

Gloria Iacoboni • 15 Apr 2024

Using lineage tracing to define responding CAR T-cells in patients with LBCL

Zinaida Good • 9 Apr 2024